OUTCOMES OF HEPATITIS B AND TUBERCULOSIS SCREENING IN A COHORT OF PATIENTS ON BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (BDMARDS) FOR RHEUMATIC DISEASE AT A MELBOURNE PUBLIC HOSPITAL

被引：0
|
作者：
Pourhadi, H. [1 ]
Johnson, A. [1 ]
Foote, A. [1 ]
机构：
[1] Northern Hlth, Rheumatol, Epping, NSW, Australia
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
关键词：
Vaccination/Immunization; bDMARD; Quality of care;
D O I：
10.1136/annrheumdis-2023-eular.5494
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB1618
引用
收藏
页码：2043 / 2044
页数：2
相关论文
共 50 条
  • [31] Decreased chronic kidney disease in rheumatoid arthritis in the era of biologic disease-modifying anti-rheumatic drugs
    Hanaoka, Hironari
    Kikuchi, Jun
    Hiramoto, Kazuoto
    Saito, Shuntaro
    Kondo, Yasushi
    Kaneko, Yuko
    CLINICAL KIDNEY JOURNAL, 2022, 15 (07) : 1373 - 1378
  • [32] Lipid screening and statins alongside disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis
    Navarro-Millan, Iris
    Goyal, Parag
    Safford, Monika M.
    RHEUMATOLOGY, 2019, 58 (06) : 933 - 934
  • [33] SERUM TROUGH LEVELS OF BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (BDMARDS) INVERSELY CORRELATE WITH DISEASE ACTIVITY IN PATIENTS WITH INFLAMMATORY ARTHRITIS
    Wong, Peter
    Bowling, Alison
    Bagga, Hanish
    Giammichele, Ms Demi Rose
    Hobson, Peter
    Langguth, Daman
    INTERNAL MEDICINE JOURNAL, 2020, 50 : 25 - 25
  • [34] Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs
    Pavelka, Karel
    Kavanaugh, Arthur F.
    Rubbert-Roth, Andrea
    Ferraccioli, Gianfranco
    RHEUMATOLOGY, 2012, 51 : V12 - V21
  • [35] Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs
    Michelena, Xabier
    Borrell, Helena
    Lopez-Corbeto, Mireia
    Lopez-Lasanta, Maria
    Moreno, Estefania
    Pascual-Pastor, Maria
    Erra, Alba
    Serrat, Mayte
    Espartal, Esther
    Anton, Susana
    Anez, Gustavo Adolfo
    Caparros-Ruiz, Raquel
    Pluma, Andrea
    Trallero-Araguas, Ernesto
    Barcelo-Bru, Mireia
    Almirall, Miriam
    De Agustin, Juan Jose
    Llados, Jordi
    Julia, Antonio
    Marsal, Sara
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2020, 50 (04) : 564 - 570
  • [36] Comparative safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs for cardiovascular outcomes in rheumatoid arthritis
    Sendaydiego, Xavier
    Gold, Laura S.
    Dubreuil, Maureen
    Andrews, James S.
    Reid, Pankti
    Liew, David F. L.
    Goulabchand, Radjiv
    Hughes, Grant C.
    Sparks, Jeffrey A.
    Jarvik, Jeffrey G.
    Singh, Siddharth
    Liew, Jean W.
    Singh, Namrata
    RHEUMATOLOGY, 2025,
  • [37] Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
    Agarwal, S.
    Zaman, T.
    Handa, R.
    SINGAPORE MEDICAL JOURNAL, 2009, 50 (07) : 686 - 692
  • [38] Methotrexate Use and the Risk for Cardiovascular Disease Among Rheumatoid Patients Initiating Biologic Disease-Modifying Anti-Rheumatic Drugs
    Xie, Fenglong
    Chen, Lang
    Levitan, Emily
    Muntner, Paul M.
    Curtis, Jeffrey R.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [39] Therapeutic Utility and Adverse Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs in Inflammatory Arthritis
    Min, Hong Ki
    Kim, Se Hee
    Kim, Hae-Rim
    Lee, Sang-Heon
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (22)
  • [40] Cardiovascular Risk of Synthetic, Non-Biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
    Mourouzis, Iordanis S.
    Manolis, Antonis S.
    Pantos, Constantinos
    CURRENT VASCULAR PHARMACOLOGY, 2020, 18 (05) : 455 - 462
12345